Black Diamond Therapeutics, Inc. Common Stock

BDTXNASDAQ • USD
ThemeHealthcare - Oncology›Targeted Therapy & Precision Oncology
2.24 USD
↗ 0.09 (3.94%)AT CLOSE (11:59 AM EDT)
2.22
↘ 0.02 (1.03%)
POST MARKET (AS OF 07:30 PM EDT)
Post Market
AS OF 07:30 PM EDT
2.22
↘ 0.02 (1.03%)
🟢Market: OPEN

Black Diamond Therapeutics, Inc. Common Stock (BDTX) trades at $2.22 per share. The stock presents a mixed profile: our models indicate a Strong Buy for technical indicators, while underlying fundamentals flash a Sell. Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. On the valuation side, BDTX appears attractively valued relative to sector peers across key multiples.

Technical & fundamental data as of Aug 25, 2026.

Open?$2.19
High?$2.25
Low?$2.19
Prev. Close?$2.16
Volume?417.5K
Avg. Volume?647.9K
VWAP?$2.21
Rel. Volume?0.64x
Bid / Ask
Bid?$1.91 × 100
Ask?$2.56 × 100
Spread?$0.65
Midpoint?$2.24
Valuation & Ratios
Market Cap?124.1M
Shares Out?57.5M
Float?42.5M
Float %?74.1%
P/E Ratio?N/A
P/B Ratio?1.29
EPS?-$0.74
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
Themes
Healthcare - Oncology›Targeted Therapy & Precision OncologyBiotech - Drug Development›Clinical-Stage Platforms
Employees
21
Market Cap
123.8M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.blackdiamondtherapeutics.com
Listed
2020-01-30
Address
245 FIRST STREET, 18TH FLOOR
CAMBRIDGE, MA 02142
Phone: 617-417-5868
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+1/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
50
Short Sent.?
23
Piotroski F-Score?0/9Weak
Altman Z-Score?-3.26Distress
Confidence?54%Low
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?14.54%High
Short Interest?6.2M
Days to Cover?10.4
Free Float42.5M
Avg Daily Volume596.8K
Settlement Date2026-08-14
Financial Health
Current Ratio?7.28Strong
Quick Ratio?7.28Strong
Cash Ratio?1.21Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
91
1.29CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-2.4CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-44.3%WEAK▾
ROA?
S&P
3
-34.0%WEAK▾
Cash Flow & Enterprise
FCF?$-32837000
Enterprise Value?$104.9M
Fundamentals ratios updated end of day
MarketsMoversWatchlist